The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis

Journal of Immunology

Volumn 178, Issue 12, 2007, Pages 8138-8147

  Sheibanie, Amir F ^a   Yen, Jui Hung ^a,b   Khayrullina, Tanzilya ^a,b   Emig, Frances ^a   Zhang, Ming ^a   Tuma, Ronald ^a   Ganea, Doina ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTAPROST; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; MISOPROSTOL; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2; SULPROSTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE EXACERBATION; ENTERITIS; HELPER CELL; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; TH17 CELL;

EID: 34250184097     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.12.8138     Document Type: Article

References (71)

1. Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533.
2. Shunahan, F. 2002. Crohn's disease. Lancet 359: 62-69.
3. Neurath, M. F., S. Finotto, and L. H. Glimcher. 2002. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8: 567-573.
4. Rakoff-Nahoum, S., L. Hao, and R. Medzhitov. 2006. Role of Toll-like receptors in spontaneous commensal-dependeni colitis. Immunity 25: 319-329.
5. Uhlig, H. H., B. S. McKenzie, S. Hue, C. Thompson, B. Joyce-Shaikh, R. Stepankova, N. Robinson, S. Buonocore, H. Tlaskalova-Hogenova, D. J. Cua, and F. Powrie. 2006. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25: 309-318.
6. Cobrin, G. M., and M. T. Abreu. 2005. Defects in mucosal immunity leading to Crohn's disease. Immunol. Rev. 206: 277-295.
7. Hanauer, S. B. 2006. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12(Suppl. 1): S3-S9.
8. Monteleone, G., D. Fina, R. Caruso, and F. Pallone. 2006. New mediators of immunity and inflammation in inflammatory bowel disease. Curr. Opin. Gastroenterol. 22: 361-364.
9. Alber, G., S. Al-Robaiy, M. Kleinschek, J. Knauer, P. Krumbholz, J. Richter, S. Schoeneberger, N. Schuetze, S. Schulz, K. Toepfer, et al. 2006. Induction of immunity and inflammation by interleukin-12 family members. Ernst. Schering Res. Found. Workshop 56: 107-127.
10. Bowman, E. P., A. A. Chackerian, and D. J. Cua. 2006. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr. Opin. Infect. Dis. 19: 245-252.
11. Chen, Y., C. L. Langrish, B. McKenzie, B. Joyce-Shaikh, J. S. Stumhofer, T. McClanahan, W. Blumenschein, T. Churakovsa, J. Low, L. Presta, et al. 2006. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116: 1317-1326.
12. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
13. Harrington, L. E., P. R. Mangan, and C. T. Weaver. 2006. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 18: 349-356.
14. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
15. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
16. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70.
17. Fuss, I. J., C. Becker, Z. Yang, C. Groden, R. L. Hornung, F. Heller, M. F. Neurath, W. Strober, and P. J. Mannon. 2006. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12: 9-15.
18. Nielsen, O. H., I. Kirman, N. Rudiger, J. Hendel, and B. Vainer. 2003. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 38: 180-185.
19. Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, M. A. Kleinschek, A. Owyang, J. Mattson, W. Blumenschein, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116: 1310-1316.
20. Zhang, Z., M. Zheng, J. Bindas, P. Schwarzenberger, and J. K. Kolls. 2006. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12: 382-388.
21. Beadling, C., and M. K. Slifka. 2006. Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. Arch. Immunol. Ther. Exp. 54: 15-24.
22. Hunter, C. A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5: 521-531.
23. Kang, B. Y., and T. S. Kim. 2006. Targeting cytokines of the interleukin-12 family in autoimmunity. Curr. Med. Chem. 13: 1149-1156.
24. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuehroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
25. Mangan, P. R., L. E. Harrington, D. B. O'Quinn, W. S. Helms, D. C. Bullard, C. O. Elson, R. D. Hatton, S. M. Wahl, T. R. Schoeb, and C. T. Weaver. 2006. Transforming growth factor-β induces development of the Th17 lineage. Nature 441: 231-234.
26. McKenzie, B. S., R. A. Kastelein, and D. J. Cua. 2006. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 27: 17-23.
27. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189.
28. + T cells. Immunity 16: 779-790.
29. Takeda, A., S. Hamano, A. Yamanaka, T. Hanada, T. Ishibashi, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170: 4886-4890.
30. Trinchieri, G. 2003. Inlerleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
31. Trinchieri, G., S. Pflanz, and R. A. Kastelein. 2003. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19: 641-644.
32. Villarino, A. V., J. Larkin, 3rd, C. J. Saris, A. J. Caton, S. Lucas, T. Wong, F. J. de Sauvage. and C. A. Hunter. 2005. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J. Immunol. 174: 7684-7691.
33. Batten, M., J. Li, S. Yi, N. M. Kljavin, D. M. Danilenko, S. Lucas, J. Lee, F. J. de Sauvage, and N. Ghilardi. 2006. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7: 929-936.
34. Hoeve, M. A., N. D. Savage, T. de Boer, D. M. Langenberg, R. de Waal Malefyt, T. H. Ottenhoff, and F. A. Verreck. 2006. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur. J. Immunol. 36: 661-670.
35. Stumhofer, J. S., A. Laurence, E. H. Wilson, E. Huang, C. M. Tato, L. M. Johnson, A. V. Villarino, Q. Huang, A. Yoshimura, D. Sehy, et al. 2006. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat. Immunol. 7: 937-945.
36. 2 induces IL-23 production in bone marrow-derived dendritic cells. FASEB J. 18: 1318-1320.
37. Neurath, M., I. Fuss, and W. Strober. 2000. TNBS-colitis. Int. Rev. Immunol. 19: 51-62.
38. 2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendrilic cells. J. Leukocyte Biol. 74: 868-879.
39. Chin, K. W., and K. E. Barrett. 1994. Mast cells are not essential to inflammation in murine model of colitis. Dig. Dis. Sci. 39: 513-525.
40. Gonzalez-Rey, E., N. Varela, A. F. Sheibanie, A. Chorny, D. Ganea, and M. Delgado. 2006. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 103: 4228-4233.
41. 2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell. Immunol. 223: 120-132.
42. Kiriyama, M., F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, and S. Narumiya. 1997. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122: 217-224.
43. Meyer, A. M., N. N. Ramzan, R. I. Heigh, and J. A. Leighton. 2006. Relapse of inflammatory bowel disease associated with use of nonsteroidal antiinflammatory drugs. Dig. Dis. Sci. 51: 168-172.
44. Shafiq, N., S. Malhotra, P. Pandhi, and R. Nada. 2005. Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors. Indian J. Exp. Biol. 43: 614-619.
45. Tessner, T. G., S. M. Cohn, S. Schloemann, and W. F. Stenson. 1998. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology 115: 874-882.
46. Thiefin, G., and L. Beaugerie. 2005. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 72: 286-294.
47. Zhang, L., Y. M. Lu, and X. Y. Dong. 2004. Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzene sulfonic acid. Chin. J. Dig. Dis. 5: 110-114.
48. 2 overproduction in impaired pulmonary host response following bone marrow transplantation. J. Immunol. 177: 5499-5508.
49. Kankuri, E., K. Vaali, R. Korpela, I. Paakkari, H. Vapaatalo, and E. Moilanen. 2001. Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation 25: 301-310.
50. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, and Y. Iwakura. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177: 566-573.
51. Lubberts, E., M. I. Koenders, and W. B. van den Berg. 2005. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 7: 29-37.
52. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
53. Sutton, C., C. Brereton, B. Keogh, K. H. Mills, and E. C. Lavelle. 2006. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203: 1685-1691.
54. Cruz, A., S. A. Khader, E. Torrado, A. Fraga, J. E. Pearl, J. Pedrosa, A. M. Cooper, and A. G. Castro. 2006. Cutting edge: IFN-γ regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J. Immunol. 177: 1416-1420.
55. Mathur, A. N., H. C. Chang, D. G. Zisoulis, R. Kapur, M. L. Belladonna, G. S. Kansas, and M. H. Kaplan. 2006. T-bet is a critical determinant in the instability of the IL-17-secreting T-helper phenotype. Blood 108: 1595-1601.
56. Rangachari, M., N. Mauermann, R. R. Marty, S. Dirnhofer, M. O. Kurrer, V. Komnenovic, J. M. Penninger, and U. Eriksson. 2006. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J. Exp. Med. 203: 2009-2019.
57. Becker, C. H. Dornhoff, C. Neufert, M. C. Fantini, S. Wirtz, S. Huebner, A. Nikolaev, H. A. Lehr, A. J. Murphy, D. M. Valenzuela, et al. 2006. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J. Immunol. 177: 2760-2764.
58. Schmidt, C., T. Giese, B. Ludwig, I. Mueller-Molaian, T. Marth, S. Zeuzem, S. C. Meuer, and A. Stallmach. 2005. Expression of interleukin-12- related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm. Bowel Dis. 11: 16-23.
59. Stallmach, A., T. Giese, C. Schmidt, B. Ludwig, I. Mueller-Molaian, and S. C. Meuer. 2004. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int. J. Colorectal Dis. 19: 308-315.
60. 381Gln is associated with childhood onset inflammatory bowel disease in Scotland. Gut. In press.
61. + T cell-induced colitis. Eur. J. Immunol. 33: 1073-1083.
62. Hue, S., P. Ahern, S. Buonocore, M. C. Kullberg, D. J. Cua, B. S. McKenzie, F. Powrie, and K. J. Maloy. 2006. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203: 2473-2483.
63. Kullberg, M. C., D. Jankovic, C. G. Feng, S. Hue, P. L. Gorelick, B. S. McKenzie, D. J. Cua, F. Powrie, A. W. Cheever, K. J. Maloy, and A. Sher. 2006. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203: 2485-2494.
64. Cohu, S. M., S. Schloemann, T. Tessner, K. Seibert, and W. F. Stenson. 1997. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J. Clin. Invest. 99: 1367-1379.
65. Jiang, G. L., A. Nieves, W. B. Im, D. W. Old, D. T. Dinh, and L. Wheeler. 2007. The prevention of colitis by E prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J. Pharmacol. Exp. Ther. 320: 22-28.
66. Kabashima, K., T. Saji, T. Murata, M. Nagamachi, T. Matsuoka, E. Segi, K. Tsuboi, Y. Sugimoto, T. Kobayashi, Y. Miyachi, et al. 2002. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J. Clin. Invest. 109: 883-893.
67. Morteau, O., S. G. Morham, R. Sellon, L. A. Dieleman, R. Langenbach, O. Smithies, and R. B. Sartor. 2000. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J. Clin. Invest. 105: 469-478.
68. Beltinger, J., B. C. McKaig, S. Makh, W. A. Stack, C. J. Hawkey, and Y. R. Mahida. 1999. Human colonic subepithelial myofibroblasts modulate transepithelial resistance and secretory response. Am. J. Physiol. 277: C271-C279.
69. McKaig, B. C., K. Hughes, P. J. Tighe, and Y. R. Mahida. 2002. Differential expression of TGF-β isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am. J. Physiol. 282: C172-C182.
70. Iwakura, Y., and H. Ishigame. 2006. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116: 1218-1222.
71. Zhang, Z., A. Andoh, O. Inatomi, S. Bamba, A. Takayanagi, N. Shimizu, and Y. Fujiyama. 2005. Interleukin-17 and lipopolysaccharides synergistically induce cyclooxygenase-2 expression in human intestinal myofibroblasts. J. Gastroenterol. Hepatol. 20: 619-627.